

CARACO PHARMACEUTICAL LABORATORIES LTD
Form 8-K
July 31, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 25, 2003

CARACO PHARMACEUTICAL LABORATORIES, LTD.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

MICHIGAN (STATE OR OTHER JURISDICTION OF INCORPORATION) (I.R.S. EMPLOYER IDENTIFICATION NUMBER) 38-2505723
0-24676
(COMMISSION FILE NUMBER)

1150 ELIJAH MCCOY DRIVE, DETROIT, MICHIGAN 48202
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(313) 871-8400
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1 July 25, 2003 Press Release

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On July 25, 2003, registrant announced its results of operations for the second quarter ended June 30, 2003 as set forth in the press release included as Exhibit 99.1 hereto.

The information in this Current Report on Form 8-K, including the exhibit, is furnished pursuant to Item 12 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in this Current Report on Form 8-K, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 8-K

Dated: July 29, 2003

CARACO PHARMACEUTICAL
LABORATORIES, LTD.
(REGISTRANT)

By: /s/ Narendra N. Borkar

Narendra N. Borkar, CEO

2

EXHIBIT INDEX

| Exhibit: | Description: |
|----------|-----------------------------|
| 99.1 | July 25, 2003 Press Release |

3